Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-096778
Filing Date
2024-11-12
Accepted
2024-11-12 16:05:31
Documents
62
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0219583-10q_hoththera.htm   iXBRL 10-Q 777084
2 CERTIFICATION ea021958301ex31-1_hoththera.htm EX-31.1 11953
3 CERTIFICATION ea021958301ex31-2_hoththera.htm EX-31.2 12007
4 CERTIFICATION ea021958301ex32-1_hoththera.htm EX-32.1 4172
5 CERTIFICATION ea021958301ex32-2_hoththera.htm EX-32.2 4122
  Complete submission text file 0001213900-24-096778.txt   5277762

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE hoth-20240930.xsd EX-101.SCH 52444
7 XBRL CALCULATION FILE hoth-20240930_cal.xml EX-101.CAL 25894
8 XBRL DEFINITION FILE hoth-20240930_def.xml EX-101.DEF 246693
9 XBRL LABEL FILE hoth-20240930_lab.xml EX-101.LAB 451680
10 XBRL PRESENTATION FILE hoth-20240930_pre.xml EX-101.PRE 255142
65 EXTRACTED XBRL INSTANCE DOCUMENT ea0219583-10q_hoththera_htm.xml XML 599451
Mailing Address 590 MADISON AVENUE 21ST FLOOR NEW YORK NY 10022
Business Address 590 MADISON AVENUE 21ST FLOOR NEW YORK NY 10022 (646)756-2997
Hoth Therapeutics, Inc. (Filer) CIK: 0001711786 (see all company filings)

EIN.: 821553794 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38803 | Film No.: 241447967
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)